Lidocaine Hydrochloride (Jelly) interactions

Conditions

Conditions in which Lidocaine Hydrochloride (Jelly) needs care, as documented in this source.

• Cardiomyopathies

  Major

  Lidocaine is absorbed through intact skin and mucosal membranes following topical administration. Prolonged exposure, large doses, frequent applications and/or use on compromised skin or mucosa can produce systemic effects. At high plasma levels, lidocaine can cause hypotension, bradycardia, and cardiovascular collapse. Therapy with lidocaine topical should be administered cautiously in patients with shock, sinus bradyarrhythmia, or severe heart block. The recommended dosage should not be exceeded. Children and debilitated, elderly, or acutely ill patients should be given reduced dosages commensurate with their age, weight, and physical condition.

  5 sources

  1. "Product Information. Lidoderm (lidocaine topical)." Endo Laboratories LLC (2001):
  2. "Product Information. Xylocaine Jelly (lidocaine topical)." Astra-Zeneca Pharmaceuticals
  3. "Product Information. Lida Mantle (lidocaine topical)." Bradley Pharmaceuticals Inc, Fairfield, NJ.
  4. "Product Information. LMX 4 (lidocaine topical)." Ferndale Laboratories Inc (2004):
  5. "Product Information. Zingo (lidocaine topical)." Sagent Pharmaceuticals, Inc. (2008):

• Kidney Diseases

  Major

  Lidocaine topical is absorbed through intact skin and mucosal membranes. Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine. Lidocaine is primarily eliminated by the kidney. Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties. Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment. Therapy with lidocaine topical should be administered cautiously and dosing modified for repeated doses in patients with compromised renal function.

  1 source

  1. "Product Information. Zingo (lidocaine topical)." Sagent Pharmaceuticals, Inc. (2008):

• Liver Diseases

  Major

  Lidocaine topical is absorbed through intact skin and mucosal membranes. Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine. Lidocaine is rapidly and extensively metabolized by the liver. Less than 10% is eliminated unchanged in the urine. Several inactive and two active forms (MEGX and GX) have been identified. MEGX and GX exhibit antiarrhythmic and convulsant properties. The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow. Therapy with lidocaine topical should be administered cautiously and dosing modified for patients with compromised hepatic function.

  1 source

  1. "Product Information. Zingo (lidocaine topical)." Sagent Pharmaceuticals, Inc. (2008):

• Seizures

  Major

  Lidocaine topical is absorbed through intact skin and mucosal membranes. Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of lidocaine. Seizures can occur as a result of accumulation of active metabolites. Therapy with lidocaine topical should be administered cautiously to patients with or predisposed to seizure disorders.

  1 source

  1. "Product Information. Zingo (lidocaine topical)." Sagent Pharmaceuticals, Inc. (2008):

• Toothache

  Major

  Topical lidocaine is not recommended to be used in teething infants and young children, as its ingestion is dangerous and potentially fatal. Ingestion of the drug has shown to result in seizures, severe brain injury, and heart problems in children.

  1 source

  1. "Product Information. Zingo (lidocaine topical)." Sagent Pharmaceuticals, Inc. (2008):